Elon's Next Market Move Could Send Silver Soaring
Every industry Elon Musk touches explodes—from Tesla to SpaceX to AI.
And now, whispers are growing that his next move could be in silver.
Why? Because silver is the lifeblood of EVs, solar panels, and AI tech.
Without it, Tesla, SpaceX, and Starlink don't grow.
Even back in 2022, Musk hinted at Tesla entering the mining industry. And with new policies clearing the way, the timing couldn't be better.
What happens if Elon enters silver?
- Massive supply chain disruptions – Silver demand is already outpacing supply.
- Prices could surge overnight – Even rumors of Musk in silver could send markets flying.
- A historic opportunity – Investors who act before the headlines could be in for a massive windfall.
Smart money is already watching silver closely.
That's why we put together the 2026 Silver Forecast Guide—your roadmap to silver's biggest growth phase yet.
Click Here to Get your Free Copy Before Silver Moves >>
Because once Musk makes a move, the window to act disappears.
3 Undervalued Names Too Cheap to Ignore
Authored by Nathan Reiff. Article Posted: 3/7/2026.
Key Points
- Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: [Sponsorship-Ad-6-Format3]
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 look like a poor time to pursue a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth.
The companies below represent potential value plays, featuring valuation metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, such as compelling dividends or promising new product developments. While clear value opportunities can be harder to find when many companies have regained investor attention—and some apparent bargains hide deteriorating operations—well-established and stable names can still be attractive prospects.
Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works
Economist who Predicted 2008 and 2020 Crashes: "Prepare for AI Meltdown" (Ad)
He's the famous economist and best-selling author who predicted the 2008 meltdown just three weeks before Lehman Brothers imploded and the Covid meltdown just three weeks before the stock market suffered the fastest drop in history. He's now predicting we're about to see an AI meltdown of historic proportions, similar to what happened in 2000 during the dotcom bust when the stock market crashed almost 80%, ruining the retirement of millions of Americans, warning that the most important AI company in the world is about to go bust in a meltdown 10 times bigger than Lehman Brothers.
See the five simple steps to prepare nowAlthough shares have climbed more than 28% over the past year, bringing Merck & Co. Inc.'s market capitalization to nearly $300 billion, the biopharma giant (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical-industry average of roughly 27. Analysts expect continued growth: Merck is projected to see earnings rise by nearly 10% in the coming year and has about 5% additional upside in the near term.
A key driver of Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received approval for subcutaneous injection from the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025, an increase of nearly 7% year over year. Keytruda also shows promise in ovarian cancer treatments, potentially expanding its patient base. These developments should help Merck build revenue as it prepares for Keytruda's patent exclusivity to end in 2028.
Merck's pipeline is broadening, too. The company recently reported notable phase 3 trial results for clesrovimab-cfor (branded Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health business into two units to better position the company to grow non-cancer drug sales ahead of Keytruda's patent expiration.
A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors
Campbell's (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faces pressure from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share fell by 13%. Margin improvement has been limited so far despite cost-saving initiatives.
The near term will likely remain challenging for the iconic brand, as guidance for the fiscal year is weak overall. However, improvements in the supply chain and strong brand loyalty—especially for premium offerings—should help protect market share. Evolving tariff dynamics could also ease some of the pressure.
Additionally, Campbell's remains a notable dividend play, yielding about 5.9%, though its payout ratio is relatively high at over 80%. Its P/E ratio of 13.5 is the lowest in roughly four years, which may persuade some investors the stock is worth the risk despite Wall Street's cautious outlook.
A Recent US Foods Rally May Continue; Bottom-Line Growth Remains in Place
Foodservice distribution leader US Foods (NYSE: USFD) has seen an almost opposite trajectory to Campbell's—in the past year, shares climbed about 33%. Even so, its valuation remains reasonable relative to some peers, with a P/E ratio around 31.6.
On the fundamentals, US Foods is making meaningful progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year over year. Better inventory management and savings on cost of goods sold are helping the company regain traction. With a $4 billion capital deployment plan, US Foods is well positioned to sustain revenue momentum and continue expanding adjusted EBITDA.
Analysts view USFD as a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential.
The SpaceX IPO Could Be the Biggest Ever—Here's What We Know
Authored by Thomas Hughes. Article Posted: 3/10/2026.
Key Points
- A SpaceX IPO is anticipated before mid-year, leaving investors wondering when and how the deal will go down.
- SpaceX is critical to the space industry, dominating a market expected to grow at a double-digit CAGR for years.
- Buying the stock is as risky as waiting, as high demand and a robust outlook suggest a high price at the start, higher prices down the road, and volatility in between.
- Special Report: [Sponsorship-Ad-6-Format3]
While not yet confirmed, rumors are building that SpaceX will pursue an initial public offering (IPO). Expected to be announced before mid-2026, such a listing would likely funnel significant capital into space stocks, not just SpaceX. Valuation estimates near $1.5 trillion would make this one of the largest IPOs in history, if not the largest.
Some reports suggest the IPO could arrive as early as Q2 2026 and that SpaceX may file confidentially with the SEC to streamline the process. A confidential filing would let the company keep sensitive details private, control messaging, and potentially reduce volatility around the offering.
Starlink Is Central to the SpaceX IPO
Economist who Predicted 2008 and 2020 Crashes: "Prepare for AI Meltdown" (Ad)
He's the famous economist and best-selling author who predicted the 2008 meltdown just three weeks before Lehman Brothers imploded and the Covid meltdown just three weeks before the stock market suffered the fastest drop in history. He's now predicting we're about to see an AI meltdown of historic proportions, similar to what happened in 2000 during the dotcom bust when the stock market crashed almost 80%, ruining the retirement of millions of Americans, warning that the most important AI company in the world is about to go bust in a meltdown 10 times bigger than Lehman Brothers.
See the five simple steps to prepare nowStarlink's profitability is a key determinant of SpaceX's IPO readiness and valuation. Starlink operates a growing constellation of low-Earth-orbit satellites that provide global internet connectivity. If Starlink can produce steady, predictable cash flow, it would help fund SpaceX's capital-intensive launch and Starship programs and reduce reliance on external financing.
Reports also suggest SpaceX may seek to raise roughly $50 billion in the offering — a sizable war chest for any company.
Why SpaceX Is a Keystone of the Commercial Space Industry
SpaceX matters because it is the largest commercial space operator, estimated to command roughly 70%–80% of certain launch and service segments, with an accelerating launch cadence. The company is on track to exceed 2025's record pace by a wide margin, having launched multiple rockets weekly from each of its bases through early March 2026.
Its customers range from governments to commercial customers needing launch, resupply, and satellite services, as well as private users — in addition to more than 10 million active Starlink subscribers.
The industry also has structural tailwinds. Governments, particularly in the United States, have shifted more activity to commercial providers. Industry estimates put the private space economy at about $625 billion in early 2026, with a roughly 12% compound annual growth rate (CAGR) expected over the next several years.
Starship is SpaceX's long-term focus: a fully reusable, super-heavy-lift system designed to carry very large payloads (up to about 150 metric tons in some configurations). It's built to be reused frequently to lower costs and enable high launch cadence. Tests are ongoing, with more launches planned in 2026. Over time, Starship is intended to support commercial activities in near-Earth orbit, lunar missions, and eventually missions to Mars.
xAI Ties Into SpaceX and Starlink
In early 2026, SpaceX announced the acquisition of xAI, Elon Musk's AI startup that develops the Grok model. Grok is a large language model that aims for blunt, truthful answers and often delivers responses with an edgier tone.
At first glance the deal may seem unusual, but it aligns with emerging strategies to combine compute, communications, and space infrastructure. The idea is to leverage Starlink's network and SpaceX's launch capability to deploy compute capacity in space, where physical security and uninterrupted solar power could be advantageous.
Cost remains a major hurdle, but SpaceX appears focused on overcoming the challenge of deploying megawatts of equipment into orbit. AI is expected to be a core technology for autonomous operation of vehicles, systems, and constellations across the space industry. Proceeds from a large IPO — such as the reported $50 billion — could accelerate deployment of space-based compute and other infrastructure.
IPO Structure Unclear: Elon Wants Tesla Shareholders to Participate
One unresolved issue is the deal structure. Musk has suggested rewarding long-time supporters by giving Tesla (NASDAQ: TSLA) shareholders early access to the offering. Key questions remain: how Tesla shareholders would receive exposure and how "long-term" holders would be defined. Broadly allowing TSLA holders early entry could create intense short-term trading and volatility, which may harm the investors the plan intends to benefit.
Another proposed route is a merger with a SPAC-like vehicle. Activist investor Bill Ackman has floated the idea of merging SpaceX with Pershing Square SPARC Holdings, a special purpose acquisition rights company (SPARC). That approach could let TSLA investors receive SPARs units ahead of a traditional listing, potentially giving them pre-IPO access to equity.
The Future of Space Is Branded SpaceX
Other companies are growing, but few have SpaceX's combination of scale, capabilities, and market share. Along with Starship, Starlink, xAI, and a dominant launch business, SpaceX's breadth sets it up to be an infrastructure provider for many future space activities. If SpaceX realizes its plans, it could underpin expanded commercial operations in orbit and on the Moon, and support long-term ambitions for Mars — goals that have shaped Musk's strategy for years.
The Risk Is Significant — Don't Invest Blindly
Investing in a SpaceX IPO would carry substantial risk. It would be one of the most anticipated and heavily subscribed offerings on record, likely producing elevated opening prices and volatile trading. Potential investors will face three basic choices: buy at the open and accept the risk, try to time an entry amid swings, or wait for the market to settle and for price action to normalize. Careful due diligence and an understanding of the risks are essential before participating.
This email communication is a sponsored message from Priority Gold, a third-party advertiser of DividendStocks.com and MarketBeat.
If you have questions or concerns about your account, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. United States..